A Phase I/II trial is set to assess the therapy’s potential efficacy and safety, as well as determine an appropriate dose.

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful ...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development ...

Quantum Biopharma plans to file an application by year's end seeking FDA clearance for a Phase 2 clinical trial testing Lucid ...

Merck's immune checkpoint inhibitor Keytruda ® has been investigated in over 1,600 combination trials worldwide. With key patents scheduled to expire starting in 2028, major biopharmaceutical ...

The Food and Drug Administration (FDA) recently announced that it had identified “significant data integrity and study conduct concerns” ...

Q1 2025 Earnings Call Transcript May 12, 2025 UroGen Pharma Ltd. misses on earnings expectations. Reported EPS is $-0.92 EPS, ...

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Annou ...

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous comp ...

Rick Blum is meticulous about planning, ordering, and taking the medication he is prescribed to slow the progression of ...

A photograph with a notorious figure may be behind the Trump administration's refusal to grant a top international politician ...